Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus Fumigatus

Drug Development and Industrial Pharmacy

Volumn 33, Issue 7, 2007, Pages 703-707

  Risovic, Verica ^a   Rosland, Mike ^a   Sivak, Olena ^a   Wasan, Kishor M ^a   Bartlett, Karen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amphotericin B; Antifungal activity; Aspergillus fumigatus; Lipids; Oral formulation; Rats

Indexed keywords

AGAR; AMPHOTERICIN B; EXCIPIENT; GALACTOMANNAN; GLUCOSE; LIPID; PECEOL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG FORMULATION; HEART; INOCULATION; JUGULAR VEIN; KIDNEY; LIVER; LUNG; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SPLEEN;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRAIN; INTESTINAL ABSORPTION; MALE; MANNANS; OLEIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; STEM CELLS;

EID: 34547210762     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040601077349     Document Type: Article

References (27)

1. Blom, G. (1958). Statistical estimates and transformed beta variables (pp. 1-58). John Wiley and Sons Inc.:NY.
2. Chavanet, P., Joly, V., Rigaud, D., Bolard, J., Carbon, C., & Yenni, P. (1994). Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother., 38, 963-968.
3. Dangi, J. S., Vyas, S. P., & Dixit, V. K. (1998). Effects of various lipid-bile salt mixed micelles on the intestinal absorption of amphotericin-B in rat. Drug Dev. Ind. Pharm., 24, 631-635.
4. Egito, E. S. T., Araujo, I. B., Bolivar, P. G., Damasceno, L., & Price, J. C. (2002). Amphotericin B/Emulsion admixture interactions: An approach concerning the reduction of amphotericin B toxicity. J. Pharm. Sci., 91, 2354-2366.
5. Fagerholm, U., Johansson, M., & Lennernas, H. (1996). Comparison between permeability coefficients in rat and human jejunum. Pharm. Res., 13, 1336-1342.
6. Gates, C., & Pinney, R. J. (1993). Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther., 18, 147-153.
7. Hauss, D. J., Fogal, S. E., Ficorilli, J. V., Price, C. A., Roy, T., Jayaraj, A. A., & Kerns, J. J. (1998). Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci., 87, 164-169.
8. Holm, R., Porter, C. J., Mullertz, A., Kristensen, H. G., & Charman, W. N. (2002). Structured triglycerides vehicles for oral delivery of halofantrine: Examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm. Res., 19, 1354-1361.
9. Kararli, T. T. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos., 16, 351-380.
10. Lance, M. R., Washington, C., & Davis, S. S. (1995). Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J. Antimicrob. Chemother., 36, 119-128.
11. Levet-Trafit, B., Gruyer, M. S., Marjanovic, M., & Chou, R. C. (1996). Estimation of oral drug absorption in man based on intestine permeability in rats. Life Sci., 58, PL359-363.
12. Manfredi, R., & Chiodo, F. (1998). Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS. Pharmacotherapy, 18, 1087-1092.
13. Marr, K. A., Balajec, S. A., McLaughlin, L., Tabouret, M., Bentsen, C., & Walsh, T. J. (2004). Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables the affect performance. J. Infect. Dis., 190, 641-649.
14. Meyer, R. D. (1992). Current role of therapy with amphotericin B. Clin. Infect. Dis., 14, S154-S160.
15. Porter, C. J., & Charman, W. N. (2001). Intestinal lymphatic drug transport: An update. Adv. Drug Deliv. Rev., 50(1-2), 61-80.
16. Reymond, J. P., Sucker, H., & Vonderscher, J. (1988). In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res., 5, 677-679.
17. Risovic, V., Boyd, M., Choo. E., & Wasan, K. M. (2003). Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob. Agents Chemother., 47(10), 3330-3342.
18. Risovic, V., Sachs-Barrable, K., Boyd, M., & Wasan, K. M. (2004). Potential Mechanisms by which Peceol increases gastrointestinal absorption of Amphotericin B. Drug Dev. Ind. Pharm., 30(7), 767-774.
19. Sivak, O., Bartlett, K., Risovic, V., Choo, E., Marra, F., Batty, D. S., & Wasan, K. M. (2004). Assessing the antifungal activity and toxicity profile of Amphotericin B Lipid Complex (ALBC; Abelcet®) in combination with Caspofungin in experimental systemic aspergillosis. J. Pharm. Sci., 93(6), 1382-1389.
20. Soria, I., & Zimmerman, C. L. (1996). The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats. Biopharm. Drug Dispos., 17, 817-818.
21. Souza, L. C., & Campa, A. (1999). Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion. J. Antimicrob. Chemother., 44, 77-84.
22. Souza, L. C., Maranhao, R. C., Schreier, S., & Campa, A. (1993). In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J. Antimicrob. Chemother., 32, 123-132.
23. Souza, L. C., Saldiva, P. H., & Campa, A. (2000). Lipid emulsion reduces subacute toxicity of amphotericin B: A histopathological study. Exp. Toxicol. Pathol., 52, 169-175.
24. Wasan, K. M. (2002). The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm., 28, 1047-1058.
25. Wasan, K. M., Grossie, V. B. Jr., & Lopez-Berestein, G. (1994). Concentrations in serum and tissue distribution of free and liposomal amphotericin B in rats on continuous Intralipid infusion. Antimicrob. Agents Chemother., 38, 2224-2226.
26. Wasan, K. M., Kennedy, A. L., Cassidy, S. M., Ramaswamy, M., Holtorf, L., Chou, J. W. L., & Pritchard, P. H. (1998). Pharmacokinetics, Distribution in Serum Lipoprotein and Tissues and Renal Toxicities of Amphotericin B and Amphotericin B Lipid Complex in a Hypercholesterolemic Rabbit Model: Single Dose Studies. Antimicrob. Agents Chemother., 42, 3146-3152.
27. Wasan, K. M., Vadiei, K., Lopez-Berestein, G., & Luke, D. R. (1990). Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis., 161, 562-566.